Strategic collaboration at Sanford, North Carolina facility, currently under construction, to optimize cGMP validation, accelerate time-to-market for complex biologics, and shore up U.S. medicine ...
With an upfront payment of $100 million, Kyowa Kirin has bought into a partnership with BridgeBio to develop and commercialize Truseltiq (infigratinib) in Japan. Besides the sizable upfront ...
Kyowa Kirin is expanding its scope to genetic medicines by acquiring Orchard Therapeutics, a company whose gene therapy for a rare inherited metabolic disorder is commercialized in Europe and is on ...
"Partnering with Bioz has been a great experience," said Matthias Stiemer, Overseas Sales Department at Kyowa Interface Science. "We're already seeing excellent engagement from researchers exploring ...
TOKYO, Feb. 6, 2024 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announced the enrollment of the first patient in a Phase 2 clinical trial, multi-center, randomized, double-masked, parallel ...
Kyowa Kirin (TSE:4151) Valuation in Focus Following Orphan Drug Designation for OTL-200 Gene Therapy
Kyowa Kirin (TSE:4151) recently announced that Japan's Ministry of Health, Labor and Welfare has granted Orphan Regenerative Medicine Product Designation to OTL-200, an investigational gene therapy ...
Like many other biopharma companies, Kyowa Kirin is in restructuring mode. The Japanese pharma is planning “a significant reduction” in its small molecule drug discovery research activities, the ...
Despite reporting proof-of-concept results in a mid-stage trial, Kyowa Kirin has decided to discontinue development of its Parkinson's disease candidate KW-6356, a drug in the adenosine A2A receptor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results